Matches in SemOpenAlex for { <https://semopenalex.org/work/W3113183960> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W3113183960 endingPage "ii46" @default.
- W3113183960 startingPage "ii46" @default.
- W3113183960 abstract "Abstract BACKGROUND We report phase I data examining pharmacokinetics, safety and preliminary efficacy of the dimeric, pan-RAF inhibitor DAY101 (formerly TAK-580/MLN2480) in pediatric patients with radiographically recurrent/progressive LGGs harboring MEK/ERK pathway alterations. METHODS Oral DAY101 was administered weekly to patients < 18 years of age with radiographically recurrent/progressive LGG for 4-week cycles up to a maximum of 2 years. The starting DAY101 dosage was 280 mg/m2. Dose limiting toxicities were determined after one cycle. RESULTS We treated nine eligible patients at 280, 350, and 420 mg/m2. Seven patients had KIAA1549:BRAF fusions, one a novel SRGAP3-RAF1 gene fusion and one with NF1 mutation. PK parameters following weekly administration of DAY101 in children mirrored the adult data, with dose-proportional increases in Cmax and AUC observed. There were no DLTs. The most common toxicity was skin rash followed by achromotrichia and nevi formation. There was only one grade 3 elevation is CPK and no grade 4 adverse events. A 2.2-fold mg/kg exposure difference was observed with respect to weight-based dosing and suggested a correlation to independent, centrally reviewed best radiographic RANO responses of 2 complete responses, 2 partial responses, 3 stable disease, and 2 progressive disease. Median time to response was 10.5 weeks (range: 8–32 weeks). CONCLUSIONS These phase 1 data provide initial pharmacokinetic parameters outlining oral weekly dosing of DAY101 in pediatric patients with radiographically recurrent and progressive LGG. Plasma exposures of DAY101 are similar in children and adults. Oral weekly DAY101 is well-tolerated and shows anti-tumor activity. The amended protocol explores differential dosing to achieve similar responses across a variety of body surface areas." @default.
- W3113183960 created "2020-12-21" @default.
- W3113183960 creator A5007118538 @default.
- W3113183960 creator A5046264008 @default.
- W3113183960 creator A5048329298 @default.
- W3113183960 creator A5066809288 @default.
- W3113183960 creator A5068793931 @default.
- W3113183960 creator A5084156179 @default.
- W3113183960 creator A5085032736 @default.
- W3113183960 creator A5090423495 @default.
- W3113183960 date "2020-11-01" @default.
- W3113183960 modified "2023-10-15" @default.
- W3113183960 title "CTNI-19. PHASE I TRIAL OF DAY101 IN PEDIATRIC PATIENTS WITH RADIOGRAPHICALLY RECURRENT OR PROGRESSIVE LOW-GRADE GLIOMA (LGG)" @default.
- W3113183960 doi "https://doi.org/10.1093/neuonc/noaa215.186" @default.
- W3113183960 hasPublicationYear "2020" @default.
- W3113183960 type Work @default.
- W3113183960 sameAs 3113183960 @default.
- W3113183960 citedByCount "5" @default.
- W3113183960 countsByYear W31131839602022 @default.
- W3113183960 countsByYear W31131839602023 @default.
- W3113183960 crossrefType "journal-article" @default.
- W3113183960 hasAuthorship W3113183960A5007118538 @default.
- W3113183960 hasAuthorship W3113183960A5046264008 @default.
- W3113183960 hasAuthorship W3113183960A5048329298 @default.
- W3113183960 hasAuthorship W3113183960A5066809288 @default.
- W3113183960 hasAuthorship W3113183960A5068793931 @default.
- W3113183960 hasAuthorship W3113183960A5084156179 @default.
- W3113183960 hasAuthorship W3113183960A5085032736 @default.
- W3113183960 hasAuthorship W3113183960A5090423495 @default.
- W3113183960 hasBestOaLocation W31131839601 @default.
- W3113183960 hasConcept C112705442 @default.
- W3113183960 hasConcept C126322002 @default.
- W3113183960 hasConcept C141071460 @default.
- W3113183960 hasConcept C197934379 @default.
- W3113183960 hasConcept C22979827 @default.
- W3113183960 hasConcept C2776694085 @default.
- W3113183960 hasConcept C2777288759 @default.
- W3113183960 hasConcept C2778570526 @default.
- W3113183960 hasConcept C2778715236 @default.
- W3113183960 hasConcept C2778822529 @default.
- W3113183960 hasConcept C29730261 @default.
- W3113183960 hasConcept C71924100 @default.
- W3113183960 hasConcept C90924648 @default.
- W3113183960 hasConceptScore W3113183960C112705442 @default.
- W3113183960 hasConceptScore W3113183960C126322002 @default.
- W3113183960 hasConceptScore W3113183960C141071460 @default.
- W3113183960 hasConceptScore W3113183960C197934379 @default.
- W3113183960 hasConceptScore W3113183960C22979827 @default.
- W3113183960 hasConceptScore W3113183960C2776694085 @default.
- W3113183960 hasConceptScore W3113183960C2777288759 @default.
- W3113183960 hasConceptScore W3113183960C2778570526 @default.
- W3113183960 hasConceptScore W3113183960C2778715236 @default.
- W3113183960 hasConceptScore W3113183960C2778822529 @default.
- W3113183960 hasConceptScore W3113183960C29730261 @default.
- W3113183960 hasConceptScore W3113183960C71924100 @default.
- W3113183960 hasConceptScore W3113183960C90924648 @default.
- W3113183960 hasIssue "Supplement_2" @default.
- W3113183960 hasLocation W31131839601 @default.
- W3113183960 hasLocation W31131839602 @default.
- W3113183960 hasLocation W31131839603 @default.
- W3113183960 hasOpenAccess W3113183960 @default.
- W3113183960 hasPrimaryLocation W31131839601 @default.
- W3113183960 hasRelatedWork W2051764329 @default.
- W3113183960 hasRelatedWork W2064759457 @default.
- W3113183960 hasRelatedWork W2800682907 @default.
- W3113183960 hasRelatedWork W3042563287 @default.
- W3113183960 hasRelatedWork W3091827932 @default.
- W3113183960 hasRelatedWork W3113183960 @default.
- W3113183960 hasRelatedWork W3151787567 @default.
- W3113183960 hasRelatedWork W3185247380 @default.
- W3113183960 hasRelatedWork W3207313530 @default.
- W3113183960 hasRelatedWork W4220955662 @default.
- W3113183960 hasVolume "22" @default.
- W3113183960 isParatext "false" @default.
- W3113183960 isRetracted "false" @default.
- W3113183960 magId "3113183960" @default.
- W3113183960 workType "article" @default.